Economic incentives for evidence generation: Promoting an efficient path to personalized medicine

Value in Health

Volumn 16, Issue 6 SUPPL., 2013, Pages

  Towse, Adrian ^a   Garrison, Louis P ^b  

^a OFFICE OF HEALTH ECONOMICS   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

economic incentives; personalized medicine; pharmacogenetics; stratified medicine

Indexed keywords

ARTICLE; COMPETITION; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EXPECTATION; HEALTH CARE SYSTEM; HUMAN; INVESTMENT; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; REIMBURSEMENT; RISK ASSESSMENT;

ECONOMIC INCENTIVES; PERSONALIZED MEDICINE; PHARMACOGENETICS; STRATIFIED MEDICINE;

COOPERATIVE BEHAVIOR; COSTS AND COST ANALYSIS; DATA COLLECTION; EVIDENCE-BASED PRACTICE; HUMANS; INDIVIDUALIZED MEDICINE; MOTIVATION; PATENTS AS TOPIC;

EID: 84884196382     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.06.003     Document Type: Article

References (21)

1. O'Donnell JC. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value Health 2013;16(Suppl.):S1-3.
2. Redekop K, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health 2013;16(Suppl.):S4-9.
3. M.R. Trusheim, E.R. Berndt, and F.L. Douglas Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers Nat Rev Drug Discov 6 2007 287 293
4. Interview with Dr. Francis Collins, Director of the Human Genome Project at the National Institutes of Health. Religion Ethics Newsweekly. Available from: http://www.pbs.org/wnet/religionandethics/episodes/june-16-2000/ transcript-bob-abernethys-interview-with-dr-francis-collins-director-of-the- human-genome-project-at-the-national-institutes-of-health/15204/. [Accessed July 26, 2013].
5. Garrison LP, Veenstra DL, Carlson RJ, et al. Backgrounder on Pharmacogenomics for the Pharmaceutical and Biotechnology Industries: Basic Science, Future Scenarios, Policy Directions. Report. Pharmaceutical Outcomes Research Policy and Program, Department of Pharmacy, University of Washington, February 2007.
6. E. Faulkner, L. Annemans, L. Garrison Personalized Medicine Development and Reimbursement Working Group Challenges in the development and reimbursement of personalized medicine - payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR Personalized Medicine Special Interest Group Value Health 15 2012 1162 1171
7. L.P. Garrison, and A. Towse Economics of personalized medicine: pricing and reimbursement policies as a potential barrier to development and adoption AJ. Culyer, Encyclopedia of Health Economics 2014 Elsevier
8. Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health 2013;16(Suppl.):S20- 6.
9. Payne K, Annemans L. Reflections on market access for personalized medicine: recommendations for Europe. Value Health 2013;16(Suppl.):S32-8.
10. P.J. Neumann, J.T. Cohen, and J.K. Hammitt Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents Health Econ 21 2012 238 251
11. C. Henshall, T. Schuller, and L. Mardhani-Bayne Using health technology assessment to support optimal use of technologies in current practice: the challenge of "disinvestments." Int J Technol Assessment Health Care 28 2012 203 210
12. Willke RJ, Crown W, del Aguila M, et al. Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice. Value Health 2013;16(Suppl.):S10-5.
13. Frueh FW. Regulation, reimbursement, and the long road of implementation of Personalized Medicine - a perspective from the United States. Value Health 2013;16(Suppl.):S27-31.
14. P. Danzon, and A. Towse The economics of gene therapy and of pharmacogenetics Value Health 5 2002 5 13
15. Towse A, Ossa D, Veenstra D, et al. Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. J Pers Med 2013. In press.
16. Burns L, Orsini L, L'Italien G. Value-based assessment of pharmacodiagnostic testing from early stage development to real-world use. Value Health 2013;16(Suppl.):S16-9.
17. M. Garau, A. Towse, and L. Garrison Can and should value based pricing be applied to molecular diagnostics? Pers Med 10 2013 61 72
18. L.P. Garrison, and M.J.F. Austin Linking pharmacogenetics-based diagnostics and pharmaceuticals for personalized medicine: scientific and economic challenges Health Aff 25 2006 1281 1290
19. I. Miller, J. Ashtonâ€Chess, and H. Spolders Market access challenges in the EU for high medical value diagnostic tests Pers Med 8 2011 137 148
20. L.P. Garrison, and M.J.F. Austin The economics of personalized medicine: a model of incentives for value creation and capture Drug Inf J 41 2007 501 509
21. H. Grabowski Follow-on biologics: data exclusivity and the balance between innovation and competition Nat Rev Drug Discov 7 2008 479 488